Bio-Design and Manufacturing  2026 Vol.9 No.3 P.514 - 538

http://doi.org/10.1631/bdm.2500128


Comparative analysis of the safety and efficacy of 3D-bioprinted constructs embedded with human mesenchymal stem cells for bone regeneration


Author(s):  Jung Ho Jeon,Jae-Seok Kim,Hun-Jin Jeong,Eun Chae Kim,Hyeon Jun Yoon,Hye Won Kim,Eunju Hong,Man Soo Kim,Jung Yeon Lim,Minho Lee,Seung-Jae Lee,Sung Won Kim

Affiliation(s):  1. Department of Biomedicine and Health Science, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea more

Corresponding email(s):   MinhoLee@dgu.edu, MinhoLee@dgu.edu, MinhoLee@dgu.edu

Key Words:  Mesenchymal stem cells, 3D printing, Bioprinting, Acute toxicity test, Transplantation


Jung Ho Jeon. Comparative analysis of the safety and efficacy of 3D-bioprinted constructs embedded with human mesenchymal stem cells for bone regeneration[J]. Journal of Zhejiang University Science D, 2026, 9(3): 514 - 538.

@article{title="Comparative analysis of the safety and efficacy of 3D-bioprinted constructs embedded with human mesenchymal stem cells for bone regeneration",
author="Jung Ho Jeon",
journal="Journal of Zhejiang University Science D",
volume="9",
number="3",
pages="514 - 538",
year="2026",
publisher="Zhejiang University Press & Springer",
doi="10.1631/bdm.2500128"
}

%0 Journal Article
%T Comparative analysis of the safety and efficacy of 3D-bioprinted constructs embedded with human mesenchymal stem cells for bone regeneration
%A Jung Ho Jeon
%J Journal of Zhejiang University SCIENCE D
%V 9
%N 3
%P 514 - 538
%@ 1869-1951
%D 2026
%I Zhejiang University Press & Springer
%DOI 10.1631/bdm.2500128

TY - JOUR
T1 - Comparative analysis of the safety and efficacy of 3D-bioprinted constructs embedded with human mesenchymal stem cells for bone regeneration
A1 - Jung Ho Jeon
J0 - Journal of Zhejiang University Science D
VL - 9
IS - 3
SP - 514
EP - 538
%@ 1869-1951
Y1 - 2026
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/bdm.2500128


Abstract: 
Advanced therapy medicinal products are biological products that require rigorous long-term monitoring of safety and efficacy due to their sustained effects. The development of tissue-engineered products demands careful consideration of tissue-specific properties, surgical requirements, biomaterial compatibility, host tissue integration, and potential immune responses. In this study, we developed and evaluated the safety and efficacy of 3D-bioprinted constructs containing cells for bone regeneration in preclinical models. Three types of human mesenchymal stem cells (bone marrow-derived, adipose-derived, and nasal turbinate-derived) were combined with varying concentrations of collagen and polycaprolactone. Safety assessments included comprehensive tumorigenicity evaluations involving cell viability assays, protein quantification, and whole-genome sequencing under multiple conditions to confirm genetic stability and mitigate tumorigenic risks. Short-term toxicity was evaluated by subcutaneous implantation in nude mice, with blood and serum analyses confirming the absence of acute toxicity or histological abnormalities in major organs. Efficacy studies in rabbits exhibited safety through posttransplantation analyses, with 6-month tissue analyses showing significantly elevated expression of osteopontin and runt-related transcription factor 2 (RUNX2) proteins in constructs containing human nasal turbinate-derived mesenchymal stem cells, indicating successful tissue integration and bone-specific marker expression. Long-term follow-up confirmed construct integrity and sustained bone formation. These findings highlight the importance of comprehensive safety and efficacy evaluations across cell types and construct compositions in the development of 3D-bioprinted constructs for bone regeneration. This study establishes a systematic framework for material selection and validation in preclinical stages, providing a foundation for future clinical applications in regenerative medicine and tissue engineering.The alternative text for this image may have been generated using AI.

Comparative analysis of the safety and efficacy of 3D-bioprinted constructs embedded with human mesenchymal stem cells for bone regeneration

先进治疗药物 (Advanced Therapy Medicinal Products, ATMPs) 作为具有持续生物学效应的生物制品, 其安全性与有效性需经过长期、 系统的评估。 组织工程产品的研发不仅需要充分考虑组织特异性结构与功能特征, 还需兼顾临床手术需求、 生物材料相容性、 宿主组织整合能力以及潜在的免疫反应风险。 本研究构建并在多种临床前模型中系统评估了含细胞 3D 生物打印骨再生构建体的安全性与有效性。 研究选用三种人源间充质干细胞——骨髓来源、 脂肪来源及鼻甲来源间充质干细胞, 并将其与不同浓度比例的胶原蛋白与聚己内酯 (polycaprolactone, PCL) 复合, 用于构建 3D 生物打印支架。 安全性评价方面, 研究开展了全面的致瘤性评估, 包括在多种培养条件下进行的细胞活性检测、 蛋白表达定量分析以及全基因组测序, 以验证细胞遗传稳定性并降低潜在致瘤风险。 短期毒性通过将构建体皮下植入裸鼠进行评估, 血液学和血清学检测结果显示未观察到急性毒性反应, 主要脏器亦未出现明显的组织学异常。 在有效性研究中, 通过兔骨缺损模型评估构建体的成骨潜能及移植后安全性。 移植后随访分析显示, 各构建体均表现出良好的生物安全性。 6 个月组织学与分子分析结果表明, 含人源鼻甲来源间充质干细胞的构建体中骨桥蛋白 (osteopontin) 和 runt 相关转录因子 2 (RUNX2) 的表达水平显著升高, 提示构建体与宿主组织成功整合, 并诱导了特异性的成骨相关分子表达。 长期随访进一步证实了构建体结构稳定性及持续的新骨形成能力。 综上所述, 本研究强调了在 3D 生物打印骨再生构建体研发过程中, 对不同细胞来源及构建体组成进行系统性安全性与有效性评估的重要性。 该研究建立了一套用于临床前阶段材料筛选与验证的系统化评价框架, 为 3D 生物打印技术在再生医学与组织工程领域的临床转化奠定了坚实基础。
Mesenchymal stem cells; 3D printing; Bioprinting; Acute toxicity test; Transplantation

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Full Text:   <5>

CLC number: 

On-line Access: 2026-05-25

Received: 2025-03-17

Revision Accepted: 2025-08-31

Crosschecked: 0000-00-00

Cited: 

Clicked: 18

Citations:  Bibtex RefMan EndNote GB/T7714

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2026 Journal of Zhejiang University-SCIENCE